Sensorion SA (ALSEN.PA)
EUR 0.17
(7.33%)
EUR 0.17
(7.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.78 Million EUR | -9.02% |
| 2022 | 4.16 Million EUR | 11.01% |
| 2021 | 3.75 Million EUR | 93.62% |
| 2020 | 1.93 Million EUR | -10.03% |
| 2019 | 2.15 Million EUR | 14.31% |
| 2018 | 1.88 Million EUR | 21.58% |
| 2017 | 1.54 Million EUR | 122.92% |
| 2016 | -6.75 Million EUR | -91.02% |
| 2015 | -3.53 Million EUR | -1628.01% |
| 2014 | 231.56 Thousand EUR | 136.59% |
| 2013 | -632.93 Thousand EUR | -373.18% |
| 2012 | 231.69 Thousand EUR | 566.48% |
| 2011 | -49.66 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.56 Million EUR | 0.0% |
| 2023 Q2 | 2.07 Million EUR | 0.0% |
| 2023 Q4 | 2.53 Million EUR | 0.0% |
| 2023 FY | 3.78 Million EUR | -9.02% |
| 2022 Q2 | 1.51 Million EUR | 0.0% |
| 2022 FY | 4.16 Million EUR | 11.01% |
| 2022 Q4 | 2.64 Million EUR | 0.0% |
| 2021 Q2 | 1.38 Million EUR | 0.0% |
| 2021 Q4 | 2.36 Million EUR | 0.0% |
| 2021 FY | 3.75 Million EUR | 93.62% |
| 2020 Q4 | 1.26 Million EUR | 0.0% |
| 2020 Q2 | 675.73 Thousand EUR | 0.0% |
| 2020 FY | 1.93 Million EUR | -10.03% |
| 2019 Q2 | 826.78 Thousand EUR | 0.0% |
| 2019 FY | 2.15 Million EUR | 14.31% |
| 2019 Q4 | 1.31 Million EUR | 0.0% |
| 2018 Q2 | 1.25 Million EUR | 0.0% |
| 2018 Q4 | 971.58 Thousand EUR | 0.0% |
| 2018 FY | 1.88 Million EUR | 21.58% |
| 2017 FY | 1.54 Million EUR | 122.92% |
| 2017 Q4 | 886.98 Thousand EUR | 0.0% |
| 2017 Q2 | 1.04 Million EUR | 0.0% |
| 2016 FY | -6.75 Million EUR | -91.02% |
| 2016 Q2 | 1.08 Million EUR | 0.0% |
| 2016 Q4 | -7.84 Million EUR | 0.0% |
| 2015 FY | -3.53 Million EUR | -1628.01% |
| 2015 Q4 | -3.98 Million EUR | 0.0% |
| 2015 Q2 | 449.94 Thousand EUR | 0.0% |
| 2014 FY | 231.56 Thousand EUR | 136.59% |
| 2014 Q4 | -915.6 Thousand EUR | 0.0% |
| 2014 Q3 | - EUR | -100.0% |
| 2014 Q2 | 223.87 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 FY | -632.93 Thousand EUR | -373.18% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 FY | 231.69 Thousand EUR | 566.48% |
| 2012 Q1 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q3 | - EUR | 0.0% |
| 2011 FY | -49.66 Thousand EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -512.923% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 3.223% |
| Adocia SA | 1.38 Million EUR | -173.492% |
| Aelis Farma SA | 12.35 Million EUR | 69.349% |
| Biophytis S.A. | -803 Thousand EUR | 571.714% |
| Advicenne S.A. | 1.42 Million EUR | -165.628% |
| genOway Société anonyme | 20.1 Million EUR | 81.155% |
| IntegraGen SA | 5.01 Million EUR | 24.519% |
| Medesis Pharma S.A. | -2.66 Million EUR | 242.146% |
| Neovacs S.A. | 29.31 Thousand EUR | -12821.682% |
| NFL Biosciences SA | -56.06 Thousand EUR | 6856.318% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -75.941% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 366.884% |
| Theranexus Société Anonyme | -4.63 Million EUR | 181.658% |
| TME Pharma N.V. | -127 Thousand EUR | 3082.569% |
| Valbiotis SA | 2.66 Million EUR | -41.974% |
| TheraVet SA | -530.79 Thousand EUR | 813.619% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -198.963% |
| DBV Technologies S.A. | 4.15 Million EUR | 8.937% |
| Genfit S.A. | 28.22 Million EUR | 86.579% |
| GeNeuro SA | -293.8 Thousand EUR | 1389.265% |
| Innate Pharma S.A. | -4.12 Million EUR | 191.916% |
| Inventiva S.A. | 17.5 Million EUR | 78.355% |
| MaaT Pharma SA | 1.65 Million EUR | -128.874% |
| MedinCell S.A. | 9.28 Million EUR | 59.218% |
| Nanobiotix S.A. | 36.2 Million EUR | 89.539% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -70.088% |
| Poxel S.A. | 1000.00 EUR | -378686.2% |
| GenSight Biologics S.A. | 3 Million EUR | -26.262% |
| Transgene SA | -28.4 Million EUR | 113.336% |
| Valneva SE | 52.83 Million EUR | 92.831% |